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IFN-alpha and high dose ascorbic acid (AA) have a
modest clinical benefit in HAM/TSP (Nakagawa, 1996).
We investigated the effect of ex vivo and in vitro AA
and IFN-alpha treatment on HAM/TSP PBMC and
HTLV-1-infected cell lines, respectively.
We treated cells for 48-72h ex vivo and in vitro with
low-high (10-100µg/ml) dose of AA and 1000U/ml of
IFN-alpha and quantified lymphoproliferation by [
3H]
thymidine incorporation, tetraploid DNA content and
PCNA expression (flow cytometry). Viral expression was
measured at the RNA (tax, LTR) and protein (Tax, p19)
level by RT-PCR, Western blot and ELISA, respectively.
Apoptosis was quantified by subdiploid DNA content
(flow cytometry). Th1/Th2/Th17 cytokines were quanti-
fied by cytometric bead array. AA induced a dramatic
95% decrease (control 3689±755 cpm vs. AA 121±52
cpm, p=0.001) in spontaneous, virus-driven lymphopro-
liferation and a decrease in tax and LTR transcription in
HAM/TSP PBMC. In addition, AA decreased the exa-
cerbated ex vivo IFN-gamma production in HAM/TSP
PBMC. In HTLV-1 infected cell lines (MT-2 and MT-
4), AA induced a dose-dependent increase in DNA frag-
mentation (p=0.02, p=0.005), paralleled by a decrease in
PCNA (p=0.003), as well as p19 (p<0.001) and Tax
levels. These effects appear virus-specific, since high-
dose (100µg/ml) AA did not exert a significant antiproli-
ferative or pro-apoptotic effect on PBMC of normal
donors. On top, AA displayed a superior antiprolifera-
tive, antiviral and immunomodulatory effect over IFN-
alpha in both cell lines and HAM/TSP PBMC. Consid-
ering the selective antiproliferative and antiviral effects
of AA ex vivo and in vitro, the therapeutic potential of
combination therapy with high dose AA in HAM/TSP
should be further explored.
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